David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses unanswered questions that remain with atezolizumab (Tecentriq) regarding the treatment of patients with metastatic urothelial carcinoma (mUC).

One of the biggest remaining questions with atezolizumab is finding a biomarker to determine which patients are most likely to respond to the agent, Nanus explains. More than one biomarker will likely be needed, he adds.

Additionally, the duration of treatment with atezolizumab has not yet been determined.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Immuno-Oncology

Immunotherapy in GU Cancers

The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

ASCO Annual Meeting

Conference

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC